Wada M, Hiraizumi W, Fujimoto M, Kinugasa A, Shintani S, Sawada K, Shimoyama T, Suehiro M, Fukuchi M
Fourth Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya.
Intern Med. 1995 Nov;34(11):1097-1100. doi: 10.2169/internalmedicine.34.1097.
The present report describes a patient who developed Graves' disease 3 months after inception of retreatment with higher doses of interferon-alpha 2a for chronic hepatitis C, although the initial 6-month treatment caused no serious adverse reactions. Severe hyperthyroidism continued despite discontinuation of interferon-alpha 2a, and the patient was subsequently treated with 131I. This case suggests careful evaluation of the safety of retreatment to prevent manifestation of such a complication in the retreatment of chronic hepatitis C with interferon.
本报告描述了一名患者，该患者在使用更高剂量的干扰素-α 2a对慢性丙型肝炎进行再治疗开始3个月后患上了格雷夫斯病，尽管最初的6个月治疗未引起严重不良反应。尽管停用了干扰素-α 2a，但严重的甲状腺功能亢进仍持续存在，该患者随后接受了131I治疗。该病例提示，在用干扰素对慢性丙型肝炎进行再治疗时，应仔细评估再治疗的安全性，以预防此类并发症的出现。
